1192 J ournal of Medicinal Chemistry, 2004, Vol. 47, No. 5
Anastasi et al.
(17) Fujita, T.; J unkichi, I.; Hansch, C. A new substituent, π, derived
from partition coefficients. J . Am. Chem. Soc. 1964, 19, 5175-
5180.
(18) J affe´, H. H. A reexamination of the Hammett equation. J . Chem.
Soc. 1953, 51, 191-261.
(19) Craig, P. N. Interdependency between physical parameters and
selection of substituent groups for correlation studies. J . Med.
Chem. 1971, 14, 680-684.
(20) Kalman, T. I.; Reddy, A. R. V. Chemistry and biological activity
of the 2′,3′-dideoxy-3′-fluorocytidine (DDFC). Ann. N. Y. Acad.
Sci. 1990, 616, 540-541.
(21) Vlieghe, P.; Bihel, F.; Clerc, T.; Pannecouque, C.; Witvrouw, M.;
De Clercq, E.; Salles, J .-P.; Chermann, J .-C.; Kraus, J .-L. New
3′-azido-3′-deoxythymidin-5′-yl O-(ω-hydroxyalkyl)carbonate pro-
drugs: Synthesis and anti-HIV evaluation. J . Med. Chem. 2001,
44, 777-786.
(22) Vlieghe, P.; Clerc, T.; Pannecouque, C.; Witvrouw, M.; De Clercq,
E.; Salles, J .-P.; Chermann, J .-C.; Kraus, J .-L. New 3′-azido-3′-
deoxythymidin-5′-yl O-(4-Hydroxyalkyl or -Alkenyl or -Alkyl-
epoxide)carbonate prodrugs: Synthesis and anti-HIV evaluation.
J . Med. Chem. 2001, 44, 3014-3021.
(23) Anastasi, C.; Vlieghe, P.; Hantz, O.; Schorr, O.; Pannecouque,
C.; Witvrouw, M.; De Clercq, E.; Clayette, P.; Dereuddre-
Bosquet, N.; Dormont, D.; Gondois-Rey, F.; Hirsch, I.; Kraus,
J .-L. Are 5′-O-carbamate-2′,3′dideoxythiacytidine new anti-HIV
and anti-HBV nucleoside drugs or prodrugs? Bioorg. Med. Chem.
Lett. 2003, 13, 2459-2463.
(24) Pauwels, R.; Balzarini, J .; Baba, M.; Snoeck, R.; Schols, D.;
Herdewy¨n, P.; Desmyter, J .; De Clercq, E. Rapid and automated
tetrazolium-based colorimetric assay for the detection of anti-
HIV compounds. J . Virol. Methods 1988, 20, 309-321.
(25) Chun, T. W.; Fauci, S. Latent reservoirs of HIV: Obstacles to
the eradication of virus. Proc. Natl. Acad. Sci. 1999, 96, 10958-
10961.
(26) Blankson, J . N.; Persaud, D.; Siliciano, R. F. The challenge of
viral reservoirs in HIV-1 infection. Annu. Rev. Med. 2002, 53,
557-593.
(27) Badley, A. D.; Dockrell, D.; Simpson, M.; Schut, R.; Lynch, D.
H.; Leibson, P.; Paya, C. V. Macrophage-dependent apoptosis of
CD4 + T lymphocytes from HIV-infected individuals is mediated
by FASL and tumor necrosis factor. J . Exp. Med. 1997, 185, 55-
64.
(28) Herbein, G.; Mahlknecht, U.; Batliwalla, F.; Gregersen, P.;
Pappas, T.; Butler, J .; O’Brien, W. A.; Verdin, E. Apoptosis of
CD8 + T cells is mediated by macrophages through interaction
of HIV gp120 with chemokine receptor CXCR4. Nature 1998,
395, 189-194.
(29) Gatner, S. P.; Markovits, D. M.; Markovits, M. H.; Kaplan, R.
C.; Gallo, R. C.; Popovic, M. The role of mononuclear phagocytes
in HTLV-III/LAV infection. Science 1986, 233, 215-219.
(30) Aquaro, S.; Calio, R.; Balzarini, J .; Bellocchi, M. C.; Garaci, E.;
Perno, C. F. Macrophages and HIV infection: Therapeutical
approaches towards this strategic virus reservoir. Antiviral Res.
2002, 55, 209-225.
citric acid, and extracted with CH2Cl2. The organic layers were
dried over MgSO4 and filtered to afford after purification by
flash chromatography on silica gel (CH2Cl2/MeOH, 92:8)
compound 12 (25 mg, 32%): Rf ) 0.44 (CH2Cl2/MeOH 90:10);
MS (ES+) 419 (M + H)+. Anal. (C24H26N4O3) C, H, N.
Ack n ow led gm en t. We gratefully acknowledge Pr.
K. Dudley (INSERM U-382, Universite´ Me´diterrane´e,
Luminy-Marseille, France) for manuscript revisions. We
are grateful to Liesbet de Dier and Cindy Heens for their
excellent technical assistance. This research was sup-
ported by grants from LAPHAL Laboratories and PACA
regional Council (C.A.). INSERM is acknowledged for
financial support.
Su p p or tin g In for m a tion Ava ila ble: NMR and IR spec-
troscopic data and elemental analyses of the desired com-
pounds. This material is available free of charge via the
Internet at http://pubs.acs.org.
Refer en ces
(1) Mwau, M.; McMichael, A. J . A review for HIV prevention. J .
Gene Med. 2003, 5, 3-10.
(2) Lisziewick, J .; Bakare, N.; Lori, F. Therapeutic vaccination for
future management of HIV-AIDS. Vaccine 2003, 21, 620-623.
(3) Minana, S. J .; Ganuza, M. G.; Millan, P. F.; Fernandez, M. P.
Hepatitis B vaccine immunoresponsiveness in adolescents:
A
revaccination proposal after primary vaccination. Vaccine 1996,
14, 103-106.
(4) Parang, K.; Wiebe, L. J .; Knaus, E. E. Novel approaches for
designing 5′-O-ester prodrugs of 3′-azido-2′,3′-dideoxythymidine
(AZT). Curr. Med. Chem. 2000, 7, 995-1039.
(5) Tan, X. L.; Chu, C. K.; Boudinot, F. D. Development and
optimisation of anti-HIV nucleoside analogues and prodrugs: A
review of their cellular pharmacology, structure-activity rela-
tionship and pharmacokinetics. Adv. Drug Deliv. Rev. 1999, 39,
117-151.
(6) Wiebe, L. I.; Knaus, E. E. Concepts for the design of anti-HIV
nucleoside prodrugs for treating cephalic HIV infection. Adv.
Drug Deliv. Rev. 1999, 39, 63-80.
(7) Anastasi, C.; Que´le´ver, G.; Burlet, S.; Garino, C.; Souard, F.;
Kraus, J .-L. New antiviral nucleoside prodrugs await applica-
tion. Curr. Med. Chem. 2003, 10, 1795-1813.
(8) Klecker, R. W.; Collins, J . M.; Yarchoan, R.; Thomas, R.; J enkins,
J . F.; Broder, S.; Myers, C. E. Plasma and cerebrospinal fluid
pharmacokinetics of 3′-azido-3′-deoxythymidine: A novel pyri-
midine analog, with potential application for the treatment of
patients with AIDS and related diseases. Clin. Pharmacol. Ther.
1987, 41, 407-412.
(31) Doong, S. L.; Tsai, C. H.; Schinazi, R. F.; Liotta, D. C.; Cheng,
Y.-C. Inhibition of the replication of hepatitis B virus in vitro
by 2′,3′-dideoxy-3′-thiacytidine and related analogs. Proc. Natl.
Acad. Sci. U.S.A. 1991, 88, 8495-8499.
(32) Balzarini, J .; Naesens, L.; De Clercq, E. New antiviralss
Mechanism of action and resistance development. Curr. Opin.
Microbiol. 1998, 1, 535-546.
(33) Miyoshi, I.; Taguchi, H.; Kubonishi, I.; Yoshimoto, S.; Ohtsuki,
Y.; Shiraishi, Y.; Akagi, T. Type-C virus-producing cell-lines
derivated from adult T-cell leukemia. Gann Monogr. 1982, 28,
219-228.
(34) Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C.
Detection, isolation and continuous production of cytopathic
retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.
Science 1984, 224, 497-500.
(35) Rimaniol, A. C.; Haik, S.; Martin, M.; Le Grand, R.; Boussin, F.
D.; Dereuddre-Bosquet, N.; Gras, G.; Dormont, D. Na+-depend-
ent high affinity glutamate transport in macrophages. J . Im-
munol. 2000, 164, 5430-5438.
(36) Hantz, O.; Pe´rigaud, C.; Borel, C.; J amard, C.; Zoulim, F.; Tre´po,
C.; Imbach, J . L.; Gosselin, G. The SATE pronucleotide approach
applied to acyclovir: Part II. Effects of bis(SATE)phosphotriester
derivatives of acyclovir on duck hepatitis B virus replication in
vitro and in vivo. Antiviral Res. 1999, 40, 179-187.
(37) Borel, C.; Schorr, O.; Durand, I.; Zoulim, F.; Kay, A.; Tre´po, C.;
Hantz, O. Initial amplification of duck hepatitis B virus co-
valently closed circular DNA after in vitro infection of embryonic
duck hepatocytes is increased by cell cycle progression. Hepa-
tology 2001, 34, 178-179.
(9) McBride, L. J .; Kierzek, R.; Beaucage, S. L.; Caruthers, M. H.
Nucleotide chemistry. 16. Amidine protecting groups for oligo-
nucleotide synthesis. J . Am. Chem. Soc. 1986, 108, 2040-2048.
(10) Kumar, R.; Tyrrell, D. L. J . Novel 5-vinyl pyrimidine nucleosides
with potent anti-hepatitis B virus activity. Bioorg. Med. Chem.
Lett. 2001, 11, 2917-2920.
(11) Kerr, S. G.; Kalman, T. I. Highly water-soluble lipophilic
prodrugs of anti-HIV nucleoside analogue 2′,3′-dideoxycytidine
and its 3′-fluoro derivative. J . Med. Chem. 1992, 35, 1996-2001.
(12) Mauldin, S. C.; Paget, C. J ., J r.; J ones, C. D.; Colacino, J . M.;
Baxter, A. J .; Staschke, K. A.; J ohansson, N.-G.; Vrang, L.
Synthesis and antiviral activity of prodrugs of the nucleoside
1-[2′,3′-dideoxy-3′-C-(hydroxymethyl)-â-D-erythropentofuranosyl]-
cytosine. Bioorg. Med. Chem. 1998, 6, 577-585.
(13) Cody, V.; Kalman, T. I. Conformational analysis of two anti-
HIV nucleoside analogues 2′,3′-dideoxy-3′-fluorocytidine and its
N4-dimethylaminomethylene prodrug derivative. Nucleosides
Nucleotides 1992, 11, 731-738.
(14) Vincent, S.; Mons, S.; Lebeau, L.; Mioskowski, C. N,N-dibenzyl
formamidine as a new protective group for primary amine.
Tetrahedron Lett. 1997, 38, 7527-7530.
(15) Barlow, H. C.; Bowman, K. J .; Curtin, N. J .; Calvert, A. H.;
Golding, B. T.; Loughlin, P. J .; Newell, D. R.; Smith, P. G.;
Griffin, R. J . Resistance-modifying agents. Part 7: 2,6-Disub-
situted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that in-
hibit nucleoside in the presence of R1-acid glycoprotein (AGP).
Bioorg. Med. Chem. Lett. 2000, 585-589.
(16) Ashton, P. R.; Fyfe, M. C. T.; Hickingbottom, S. K.; Menzer, S.;
Stoddart, J . F.; White, A. J .; Williams, D. J . Combining different
hydrogen-bonding motifs to self-assemble interwoven super-
structures. Chem. Eur. J . 1998, 4, 577-589.
J M0309708